THE Therapeutic Goods Administration has been advised by Novo Nordisk that its Ozempic (semaglutide) solution for injection pre-filled pen will not be available in Australia from mid-Nov through until the end of Mar next year.
The TGA has recommended that patients who are prescribed Ozempic should contact their doctor immediately to have their treatment reassessed - particularly in light of the upcoming holiday season which will see medical services limited for some weeks.
"The TGA is working with Novo Nordisk and the relevant health professional organisations to manage this serious shortage," the TGA said, adding that clinical advice on how best to manage the situation would be shortly published for health professionals.
Details have been posted on the TGA's Medicine Shortage Reports Database at tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Nov 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Nov 22
